Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01276106 · ClinicalTrials.gov registry record · Phase 2

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by TWi Biotechnology.

Completed
Registry status
Phase 2
Development phase
259
Enrollment target
20
Study locations

NCT01276106 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by TWi Biotechnology. The registered enrollment target is 259 participants, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01276106, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by TWi Biotechnology.

COMPLETED
Registry status
Phase 2
Development phase
259 participants
Enrollment target
20
Study locations

Study Summary

This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG AC-201, 25mg
  • DRUG AC-201, 50mg
  • DRUG AC-201, 75mg

Study Locations (20)

Other

  • Changhua Christian Hospital - Changhua
  • Cheng Ching General Hospital - Taichung
  • Chung Shan Medical University Hospital - Taichung
  • Kuang Tien General Hospital - Taichung
  • Cardinal Tien Hospital - Taipei
  • Taipei Medical University Hospital - Taipei
  • Taipei Medical University-Shuang Ho Hospital - Taipei

California

  • Catalina Research Institute, LLC - Chino
  • National Research Institute - Los Angeles

Florida

  • Clinical Research of South Florida - Coral Gables
  • Jacksonville Impotence Treatment Center - Jacksonville

Illinois

  • Chicago Clinical Research Institute, Inc. - Chicago
  • Clinical Investigation Specialists, Inc. - Gurnee

Ohio

  • Sterling Research Group, Ltd - Cincinnati
  • PriMed Clinical Research - Kettering

Indiana

  • Midwest Institute for Clinical Research, Inc. - Indianapolis

Kentucky

  • L-MARC Research Center - Louisville

Louisiana

  • New Orleans Center for Clinical Research - New Orleans

Trial Details

FieldValue
Enrollment Target 259 participants
Start Date 2011-01
Est. Completion 2012-03
Phase Phase 2

Sponsor

TWi Biotechnology

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01276106

The ClinicalTrials.gov registry entry for NCT01276106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The listed sponsor is TWi Biotechnology, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT01276106 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT01276106 about?

NCT01276106 is a clinical study titled "Study of AC-201 in Patients With Type 2 Diabetes Mellitus". This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.

What is the current status of trial NCT01276106?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2011-01. Estimated completion is 2012-03.

What conditions does trial NCT01276106 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT01276106?

The interventions under investigation include: Placebo (DRUG), AC-201, 25mg (DRUG), AC-201, 50mg (DRUG), AC-201, 75mg (DRUG).

Who is sponsoring clinical trial NCT01276106?

This trial is sponsored by TWi Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01276106 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.